Literature DB >> 14982737

Sequence heterogeneity and viral dynamics in cerebrospinal fluid and plasma during antiretroviral therapy.

David W Haas1.   

Abstract

Understanding of human immunodeficiency virus (HIV) neuropathogenesis has been greatly enhanced by careful analyses of postmortem brain tissue, as well as by primate models of infection with related lentiviruses. However, brain tissue from persons living with HIV infection is rarely available for study, and elegant observations from primate systems may require confirmation in humans. Because of these inherent limitations, it is important to learn as much as possible by studying cerebrospinal fluid (CSF) during HIV infection. The present discussion considers selected issues relevant to the study of CSF from HIV-infected individuals. These include a strategy to intensely sample CSF to better understand viral dynamics and the role of the brain as a pharmacologic sanctuary site, evidence for HIV sequence diversity in CSF and plasma during HIV therapy and the implications of such diversity, and the importance of host genetics relevant to studying HIV neuropathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982737     DOI: 10.1080/753312750

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  18 in total

1.  HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.

Authors:  J Drewe; H Gutmann; G Fricker; M Török; C Beglinger; J Huwyler
Journal:  Biochem Pharmacol       Date:  1999-05-15       Impact factor: 5.858

2.  Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma.

Authors:  D W Haas; L A Clough; B W Johnson; V L Harris; P Spearman; G R Wilkinson; C V Fletcher; S Fiscus; S Raffanti; R Donlon; J McKinsey; J Nicotera; D Schmidt; R E Shoup; R E Kates; R M Lloyd; B Larder
Journal:  AIDS Res Hum Retroviruses       Date:  2000-10-10       Impact factor: 2.205

3.  Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients.

Authors:  J W Chien; H Valdez; G McComsey; D McClernon; M St Clair; M M Lederman
Journal:  J Acquir Immune Defic Syndr       Date:  1999-08-01       Impact factor: 3.731

4.  Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.

Authors:  G Venturi; M Catucci; L Romano; P Corsi; F Leoncini; P E Valensin; M Zazzi
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

5.  Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection.

Authors:  D W Haas; J Stone; L A Clough; B Johnson; P Spearman; V L Harris; J Nicotera; R H Johnson; S Raffanti; L Zhong; P Bergqwist; S Chamberlin; V Hoagland; W D Ju
Journal:  Clin Pharmacol Ther       Date:  2000-10       Impact factor: 6.875

6.  Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources.

Authors:  R J Ellis; A C Gamst; E Capparelli; S A Spector; K Hsia; T Wolfson; I Abramson; I Grant; J A McCutchan
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

7.  Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.

Authors:  P Cinque; S Presi; A Bestetti; C Pierotti; S Racca; E Boeri; P Morelli; P Carrera; M Ferrari; A Lazzarin
Journal:  AIDS Res Hum Retroviruses       Date:  2001-03-20       Impact factor: 2.205

8.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

9.  Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.

Authors:  M Di Stefano; F Sabri; T Leitner; B Svennerholm; L Hagberg; G Norkrans; F Chiodi
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

10.  Discordant Human Immunodeficiency Virus Type 1 drug resistance mutations, including K103N, observed in cerebrospinal fluid and plasma.

Authors:  K T Tashima; T P Flanigan; J Kurpewski; S M Melanson; P R Skolnik
Journal:  Clin Infect Dis       Date:  2002-06-07       Impact factor: 9.079

View more
  2 in total

Review 1.  Viral and host genetic factors regulating HIV/CNS disease.

Authors:  Jeymohan Joseph; Toby Behar
Journal:  J Neurovirol       Date:  2004       Impact factor: 2.643

Review 2.  HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment.

Authors:  Serena Spudich; Francisco González-Scarano
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.